NDAORALTABLET
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEPADIN (bepridil hydrochloride) is an oral calcium channel blocker approved in 1990 for cardiovascular indications. It is a small-molecule cardioactive agent administered as a tablet with mechanisms targeting cardiac conduction and coronary vasodilation. The drug treats patients requiring anti-anginal and antiarrhythmic therapeutic effects.
LOE Approaching
With LOE approaching and no active clinical pipeline noted, commercial team size is likely contracting; roles focus on lifecycle management and market defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BEPADIN offers limited growth potential due to LOE status and low linked job count; roles emphasize market defense, pricing, and compliance. Career advancement typically requires transition to growth-stage products or portfolio-wide strategic roles within Bausch Health.
Brand ManagerSales Representative
Worked on BEPADIN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.